Testicular Cancer
A highly curable cancer found mostly in young men, presenting as a painless lump in the testicle, requiring surgery and potentially chemotherapy.
Emergency Management: Choriocarcinoma Syndrome: A massive release of hCG and cytokines leading to rapid respiratory failure and severe hemorrhage from visceral metastases, occurring shortly after initiating chemotherapy. Requires ICU management.
Testicular cancer is a malignant neoplasm originating in the testicles. Over 95% are Germ Cell Tumors (GCTs), broadly classified into Seminomas and Non-Seminomas (including embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma). It is one of the most highly curable solid neoplasms, even in the presence of widespread metastatic disease.
Detailed Overview
Testicular cancer is the most common solid malignancy affecting young men aged 15-35. It typically presents as a painless, solid testicular mass. The disease is characterized by predictable lymphatic spread to the retroperitoneal lymph nodes, followed by hematogenous spread to the lungs. The advent of Cisplatin-based combination chemotherapy in the 1970s transformed testicular cancer from a highly fatal disease to a model of curable oncology, boasting a 10-year survival rate exceeding 95%. Management involves a combination of radical surgery, chemotherapy, and sometimes retroperitoneal lymph node dissection (RPLND).
Epidemiology & Demographics
Accounts for 1% of male cancers but is the most common cancer in males aged 15-35. Incidence is ~6 per 100,000 men. Highest rates are in white men of Northern European descent. Rare in African American men.
Etiological Mechanism
The exact cause is unknown, but it is strongly associated with developmental abnormalities in utero. The precursor lesion for almost all GCTs is Germ Cell Neoplasia In Situ (GCNIS), linked to a failure of primordial germ cells to mature properly. Isochromosome 12p [i(12p)] is a pathognomonic genetic alteration found in almost all invasive GCTs.
Primary Causes
Germ Cell Neoplasia In Situ (GCNIS)
Genetic mutations (Isochromosome 12p)
GCTs arise from GCNIS, which lays dormant until puberty when hormonal changes trigger rapid proliferation and progression to invasive cancer. Seminomas remain localized to the testis longer and spread slowly via lymphatics to the retroperitoneum. They are exceptionally sensitive to radiation and chemotherapy. Non-seminomas are more aggressive, invade blood vessels early, and frequently present with metastatic disease to the lungs, liver, or brain. Choriocarcinoma variants aggressively secrete Human Chorionic Gonadotropin (hCG) and have a very high propensity for early, massive hemorrhagic brain metastases.
Diagnostic Criteria & Guidelines
Initial diagnosis via high-frequency scrotal ultrasound. Definitive tissue diagnosis and initial treatment is established simultaneously via Radical Inguinal Orchiectomy. *Never* perform a trans-scrotal biopsy, as it seeds the scrotum and alters lymphatic drainage.
Initial therapy for ALL stages is Radical Inguinal Orchiectomy. For Stage I Seminoma: Surveillance or single-dose Carboplatin. For Stage I Non-Seminoma: Surveillance or primary Retroperitoneal Lymph Node Dissection (RPLND).
Second-Line & Adjunctive Therapy
For Stage II/III or High-Risk Disease: Bleomycin, Etoposide, and Cisplatin (BEP) chemotherapy for 3-4 cycles. Residual masses post-chemotherapy in non-seminomas require surgical resection (Post-chemo RPLND).
Surgical & Procedural Management
Radical Inguinal Orchiectomy: The testicle and entire spermatic cord are removed through an incision in the groin (not the scrotum). RPLND: Major abdominal surgery to remove all lymph tissue surrounding the aorta and IVC.
Patient Counseling & Advice
Reassure the patient of the extremely high cure rate. Heavily emphasize the absolute necessity of rigorous follow-up (frequent CT scans and blood work) for surveillance protocols, as relapses are highly curable if caught early.
Follow-Up & Monitoring Schedule
Intensive surveillance for 5 years: History/physical, tumor markers (AFP, hCG, LDH) every 2-3 months, and CT scans every 4-6 months initially, spacing out over time.
Preventive Strategies
No primary prevention exists. Surgical correction of cryptorchidism before age 1 facilitates easier examination but does not completely eliminate cancer risk.
Excellent. Overall 5-year survival is >95%. Even for 'poor-prognosis' metastatic non-seminoma, cure rates remain around 50-70%.